评论
打印
India has balked at the planned $1.1bn purchase of Hyderabad-based Gland Pharma by China’s Shanghai Fosun Pharma, amid concerns about allowing a foreign takeover of a producer of the export-quality medicines.
印度正在犹豫是否批准中国上海复星医药(Shanghai Fosun Pharma) 11亿美元收购总部位于海德拉巴的印度制药商Gland Pharma的计划，主要出于对允许外资收购一家品质药品出口企业的担忧。
The two companies announced last July that Fosun would take an 86 per cent stake in Gland, which produces anti-coagulants — used in dialysis or heart surgery to prevent blood-clotting — anaesthetics and other injectable medicines, mainly for export to the US.
去年7月，两家公司宣布，复星将收购Gland 86%的股权，后者生产抗凝血剂（用于透析或心脏手术，防止血液凝固）、麻醉剂及其他注射药剂，主要出口美国。
But New Delhi’s Cabinet Committee on Economic Affairs, which must give the final greenlight for a deal already approved by various Indian ministries, has been sitting on the proposal for the past four months.
但新德里的内阁经济事务委员会(CCEA)过去4个月一直拖延审批这项收购。印度各部委已批准这笔交易，但仍须由该委员会开启最后的绿灯。
“The concern is about India losing its edge on a particular drug where it has a significant presence internationally, as well as its access to our own market,” an Indian official, who did not want to be named, told the FT.
一位不愿透露姓名的印度官员对英国《金融时报》表示：“印度担心失去在国际上拥有重要地位的特定药品上的优势，以及该药品进入我国市场。”
The official told the FT no final decision had been taken on the transaction, but that “there is a serious enough concern that it is likely to bring a negative outcome”.
这位官员对英国《金融时报》表示，对于这笔交易尚未做出最终决定，但“印方的担忧如此严重，结果很可能是交易被否决”。
Gland shareholders say they have not received any official notice of New Delhi’s objection to the deal, which is the largest proposed takeover of an Indian company by a firm from China — a country with which New Delhi has uneasy relations.
Gland的股东表示，他们尚未收到新德里否决该交易的任何官方通知，这是中国企业对印度企业提出的规模最大的一笔并购交易。中印之间目前处于关系紧张状态。
Relations between the countries have deteriorated recently following a territorial dispute in the Himalayas involving India ally Bhutan. Indian officials stressed that their concern about the Gland Pharma sale was not “country-specific”.
近期，喜马拉雅山地区涉及印度盟国不丹的一场领土争端导致中印关系恶化。印度官员强调，他们对于Gland Pharma被收购的担忧并非“针对某个国家”。
Fosun Pharma confirmed the two companies had extended the “termination date” for the deal to September 26, given the lack of a final decision from India’s CCEA.
复星医药证实，鉴于印度内阁经济事务委员会尚未作出最终决定，两家公司已将交易“终止日期”延长至9月26日。
Fosun Pharma said that the Chinese government had given all the necessary approval for the purchase to proceed.
复星医药表示，中国政府已经审批通过了这笔收购交易的所需的所有程序。
